Platinum and Platinum Pro instruments

Search documents
Quantum-Si (QSI) Q2 Revenue Falls 47%
The Motley Foolยท 2025-08-06 02:50
Core Insights - Quantum-Si (QSI) reported a significant revenue shortfall in Q2 2025, with GAAP sales of $0.59 million, missing analyst estimates of $1.11 million by nearly 46.7% [1][5] - The company maintained a gross margin of 59%, an improvement from 57% in the prior year, despite ongoing struggles with commercial traction, particularly in U.S. academic markets [2][7] - QSI's accumulated deficit increased to $644.7 million as of June 30, 2025, highlighting the need for a clear path to sales growth to address sustained losses [8][15] Financial Performance - Q2 2025 GAAP revenue was $0.59 million, down 29.8% sequentially from Q1 2025 and a 5.0% decline year-over-year from Q2 2024 [2][5] - Earnings per share (EPS) for Q2 2025 was $(0.16), consistent with the same quarter last year [2] - Adjusted total operating expenses were $23.8 million, a decrease of 2.5% from the previous year, while adjusted EBITDA was negative $22.2 million [2][8] Business Overview - Quantum-Si focuses on next-generation protein sequencing technology aimed at making protein analysis more scalable and cost-effective [3] - The company is working on the launch of its Proteus platform, expected to enhance output and automation, with a prototype scheduled for late 2025 and commercial launch in the second half of 2026 [4][9] - The firm has expanded its international distributor network to 23 partners, indicating a strategic shift towards non-U.S. and non-academic customer segments [6] Product Development and Innovation - The company continues to invest in innovation, with upcoming product launches including the Version 4 Sequencing Kit in Q3 2025 and a new Version 3 Library Preparation Kit expected later in the year [9][10] - QSI's intellectual property portfolio includes nearly 400 issued patents and close to 600 pending, providing a competitive advantage [12] Market Strategy and Outlook - Management has increased academic outreach through webinars and user groups to drive demand and adoption of its technology [11] - The company raised an additional $50 million through a direct stock offering, which should fund operations into the second quarter of 2028, providing some financial breathing room [13] - Key issues for investors include the pace of commercial adoption outside U.S. academic markets and the need for recurring consumable sales to signal instrument utilization [15]